Reuters -- Johnson & Johnson's second-quarter earnings fell 4.7 percent, hurt by the stronger dollar and patent expirations on its drugs for schizophrenia and epilepsy, but profit and revenue beat analyst forecasts and shares rose 1.6 percent.
Reuters -- Johnson & Johnson's second-quarter earnings fell 4.7 percent, hurt by the stronger dollar and patent expirations on its drugs for schizophrenia and epilepsy, but profit and revenue beat analyst forecasts and shares rose 1.6 percent.
